RGS RGS Healthcare Solutions

Generics and biosimilars

See the results of the tenders that decide your volume

For generics and biosimilar companies, tenders decide a large share of European volume. RGS shows the relevant rounds across Europe, who holds each contract today, what has won before, and the price that gives you the best expected return.

The challenge

What makes tendering hard for generics and biosimilars

01

Hundreds of rounds a year

Insurer contracts, national frameworks and hospital tenders run on different calendars in each country. Missing one can mean two years without volume.

02

Awards that are easy to misread

Multi-partner lots, ranked frameworks and partial award notices make it hard to know who really won and at what price.

03

Price set by instinct

Without comparable award history, bid prices drift between leaving margin on the table and losing on price.

What you get

How RGS helps

Discovery, award intelligence and pricing guidance on one data layer, with our team available when you need analysis or hands-on support.

Used by tender managers, tender specialists, heads of key account management for hospitals, country general managers, commercial analysts.

  • A renewal calendar by molecule, buyer and lot
  • Lot-level awards with all named partners, including insurer multi-partner splits
  • Recommended bid prices with an estimated probability of winning
  • Loss of exclusivity and biosimilar entry tracking by market
  • Support for partner-led models where your distributors do the bidding

Case study

Generics manufacturer

Reshaping a generics portfolio around where tenders are won

A leading generics manufacturer wanted to know which products were holding the portfolio back and which deserved more investment.

Portfolio review
Each product was assessed against tender demand, award prices and competitive intensity across its markets.
Clear choices
We identified products to discontinue and others that could gain share after formulation or presentation changes.
Market evidence
Each recommendation was backed by award history and price trends, so the commercial and supply teams could act on it.

Results

+20%

Revenue from the optimised portfolio

+35%

Improvement in profit margin

All case studies

Also for: Branded pharma, MedTech, Partner-led manufacturers

Questions

Questions teams ask us

How do generics companies track tenders across Europe?

Most combine alerts with spreadsheets and the memory of local teams. RGS replaces that with one calendar per molecule, buyer and lot, the result of each round and the date of the next one.

Can we see the price we lost by?

Where the buyer publishes it, yes: the winning price, the other published bids and your gap to the winner, strength by strength. Where only the winner is published, the record says so.

More questions? See all questions, how pricing works, the platform and integrations or who is behind RGS.

See what the tender data says about your portfolio

We load your products and markets before the session, so the conversation starts with your own tenders.